Reference drugs for triple combination test drug in Russia [Design Issues]

posted by PharmCat  – Russia, 2019-11-21 14:02 (464 d 05:29 ago) – Posting: # 20853
Views: 3,084

Сomprehensive article:

doi:https://doi.org/10.30895/1991-2919-2019-9-1-14-27

Over the past 10 years some new fixed combinations containing previously registered drugs were approved for use in the Russian Federation based on the results of a single clinical study of bioequivalence in healthy volunteers versus registered monocomponent reference drug. However, this practice does not fully comply with current Russian legislation.

A. V. Dobrovolskiy - Scientific Centre for Expert Evaluation of Medicinal Products ("FGBU")

Complete thread:

Activity
 Admin contact
21,357 posts in 4,459 threads, 1,492 registered users;
online 7 (0 registered, 7 guests [including 3 identified bots]).
Forum time: Saturday 19:32 CET (Europe/Vienna)

The way to do research is to attack the facts
at the point of greatest astonishment.    Celia Green

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5